Weight-Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial

Department of Health and Human Services, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-5450, USA.
Gastroenterology (Impact Factor: 13.93). 06/2009; 137(2):549-57. DOI: 10.1053/j.gastro.2009.05.007
Source: PubMed

ABSTRACT With the limited efficacy of current therapy for chronic hepatitis C, modifiable risk factors for liver disease progression are important to identify. Because obesity is associated with liver disease, we examined the effects of weight-related conditions on disease outcomes in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial.
Of 1050 patients, 985 could be evaluated for predefined progression of liver disease not related to hepatocellular carcinoma. Clinical outcomes were determined over 3.5 years for all patients and progression to cirrhosis on protocol biopsy among patients who had bridging fibrosis (56.5% of cohort) at entry.
At study entry, median body mass index was high (29.2 kg/m(2)) and accompanied by other weight-related conditions, including diabetes (24.9%), high median waist circumference, and insulin resistance (by updated homeostasis model assessment of insulin resistance; HOMA2-IR). Among noninvasive measures, HOMA2-IR was most strongly associated with outcomes with hazard ratio (HR) of 1.26 per quartile increase (95% CI, 1.09-1.45). Presence of steatosis on baseline biopsy was associated with an increased outcome rate among patients with bridging fibrosis (P < .0001) and a decreased rate among patients with cirrhosis (P = .006). Presence of Mallory bodies was associated with outcomes (HR, 1.59; 95% CI, 1.10-2.31) as was significant weight change of >or=5% in the first year after randomization (HR, 1.25 per category increase in weight, 95% CI, 1.01-1.55).
Insulin resistance, histologic features of fatty liver disease, and weight change were associated with outcomes of chronic hepatitis C. Improvement in these weight-related factors might modify disease progression.

Download full-text


Available from: Hae-Young Kim, Aug 12, 2015
  • Source
    • "However, steatosis was not associated with advanced fibrosis in the cross-sectional analysis. Fibrotic tissues might replace steatosis, which confounds the influence of steatosis in liver disease severity, based on cross-sectional observation [23]. Direct evidence linking liver PNPLA3 to fibrosis is lacking; it has been suggested that the involved mechanism might be independent of steatosis, such as the Fas-ligand-mediated apoptosis pathway [40]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background & Aims: Genetic variants of patatin-like phospholipase domain-containing 3 (PNPLA3) and diabetes are associated with liver disease severity, in patients with chronic hepatitis C (CHC) infection. We aimed at exploring their interaction in determining hepatitis C virus (HCV)-related liver fibrosis. Methods: The PNPLA3 genetic polymorphism at rs738409 was verified in 1077 biopsy-proven CHC patients. Other clinical variables, including diabetes status, were analysed for factors associated with bridging fibrosis. Results: Patients with advanced liver fibrosis had higher proportions of the GG genotype (14.5% vs. 10.4%, p = 0.06 in recessive model) and GG/GC genotype carriage (64.0% vs. 56.8%, p = 0.03 in dominant model). Stepwise logistic regression analysis revealed that factors predictive of advanced liver fibrosis included age (odds ratio [OR]: 1.02, 95% confidence intervals [CI]: 1.008-1.037, p = 0.002), diabetes (OR: 1.81, CI: 1.236-2.653, p = 0.002), alpha-fetoprotein (OR: 1.006, CI: 1.001-1.01, p = 0.01), platelet counts (OR: 1.009, CI: 1.006-1.012, p < 0.001),and PNPLA3 rs738409 CG/GG genotype (OR: 1.34, CI: 1.006-1.785, p = 0.046). When patients were grouped according to their diabetes status, the PNPLA3 genetic variants were associated with advanced liver fibrosis in diabetic patients only, but not in non-diabetic patients. The PNPLA3 gene was the most important predictive factor of bridging fibrosis in diabetic patients, using the recessive model (OR: 4.53, CI: 1.356-15.106, p = 0.014) or the dominant model (OR: 2.20, CI: 1.026-4.734, p = 0.04). Compared to non-diabetic patients, patients with the diabetes/GG genotype were more likely to have advanced liver fibrosis (OR: 8.79, CI: 2.889-26.719, p < 0.001), followed by those with diabetes/non-GG genotype (OR: 1.55, CI: 1.048-2.286, p = 0.03). Conclusions: The effect of PNPLA3 genetic variants in HCVrelated advanced liver fibrosis was enhanced in diabetic patients. The strong genetic-environmental interaction contributed to the high risk of advanced liver disease in CHC patients.
    Journal of Hepatology 10/2014; 62(3). DOI:10.1016/j.jhep.2014.10.011 · 10.40 Impact Factor
  • Source
    • "Moreover, it has been reported that IR is independently associated with histological severity and negatively affects treatment response [11] [12]. Supporting the hypothesis that IR could be a pathogenic factor shared by NAFLD and chronic HCV infection, the enhancement of insulin sensitivity improves some clinical and histological features in both liver diseases [13] [14]. While there is growing clinical evidence that IR may contribute to disease progression in NAFLD and chronic HCV infection , the extent of impairment of hepatic insulin signaling, the pathways involved, and its impact on liver injury and fibrosis in both conditions remain to be defined. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to elucidate whether hepatic insulin resistance may contribute to hepatocyte apoptosis and fibrogenesis in nonalcoholic fatty liver disease (NAFLD) and in chronic hepatitis C virus (HCV) infection. Twenty-seven nonalcoholic steatosis (NAST), 24 nonalcoholic steatohepatitis (NASH), 71 HCV, and 29 patients with histological normal liver (NL) were studied. Real-time PCR, the TUNEL assay, and Western blots were used to assess insulin-signaling molecules, hepatocyte apoptosis, antiapoptotic mediators, active caspase 3, and type I collagen in liver biopsies. HCV core-transfected human hepatocytes were used as an in vitro model. In NAFLD patients, hepatic levels of insulin receptor substrate (IRS) 1, IRS2 2, the p85α subunit of phosphatidylinositol 3-kinase (p85α), phosphorylated protein kinase B (pAkt), phosphorylated forkhead box-containing protein O subfamily-1 (FoxO), and phosphorylated 5' adenosine monophosphate-activated protein kinase (pAMPK) as well as the antiapoptotic mediators B-cell lymphoma 2 protein (Bcl-2) and myeloid cell leukemia protein-1 (Mcl-1) were significantly lower in NASH than in NAST and NL. Furthermore, hepatocyte apoptosis and increased active caspase 3 were only present in NASH. In HCV patients, hepatic insulin signaling was markedly impaired, regardless of viral genotype and the presence of steatosis paralleled with enhanced apoptosis. In cultured human hepatocytes, HCV core protein decreased pAkt and increased phosphorylation of c-Jun N-terminal kinase (JNK). This effect was more pronounced in lipid-loaded hepatocytes. Hepatic insulin signaling is impaired in NASH and HCV patients, and downregulation of insulin-sensitive targets is associated with increased apoptosis and fibrogenesis in both conditions. JNK might be a target for HCV-induced insulin resistance.
    Journal of Hepatology 08/2010; 54(1):142-52. DOI:10.1016/j.jhep.2010.06.021 · 10.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper addresses the problem of analysing both robust stability and non fragility induced by a static output feedback control law. The considered models are discrete-time linear state-space representations that are subject to polytopic uncertainties. The only restriction is that the uncertainty affecting the observation matrix is independent on the uncertainty affecting evolution and control matrices. Stability is attested by the existence of a Lyapunov function that is quadratic with respect to the state vector and depends on the uncertain parameters in a "bi-polytopic way". Fragility is also handled in this paper. This works is part of LMI framework.
    Decision and Control, 2002, Proceedings of the 41st IEEE Conference on; 01/2003
Show more